抄録
Aim: Uterine leiomyosarcoma (ULMS) is a highly aggressive and lethal disease. This malignancy remains the most common type of uterine sarcoma, affecting approximately 0.4/100 000 women each year. Our aim was to assess the treatment and prognosis of ULMS patients. Methods: A total of 14 patients were treated at our institution between January 2008 and July 2017. We retrospectively analyzed their clinicopathological variables, treatment and prognosis. Results: The median patient age was 63 years (range, 35–83 years). The largest group of patients had stage IB disease (stage IB, n = 8; IIB, n = 2; IIIB, n = 1; IVB, n = 3) and the largest group by histological subtype was ordinary (ordinary, n = 11; myxoid, n = 2; epithelioid, n = 1). Total abdominal hysterectomy and bilateral salpingo-oophorectomy were performed for all patients, with additional surgical procedures (e.g., tumor resection, lymphadenectomy) performed if necessary. Twelve patients received adjuvant chemotherapy (ACT) consisting of gemcitabine and docetaxel. Ten patients experienced recurrence and received multidisciplinary therapies, including tumor resection, chemotherapy, radiation and targeted therapies. The median observation period was 17 months (range, 5–75 months), and 11 patients were alive (without disease, n = 5; with disease, n = 6). Intriguingly, five of eight stage IB patients who received postoperative ACT were alive without disease. Conclusion: ULMS is rare but is associated with a poor prognosis, even if multidisciplinary therapies are administered. However, ACT appears to be effective in improving the prognosis of patients with stage IB disease.
| 元の言語 | 英語 |
|---|---|
| ジャーナル | Asia-Pacific Journal of Clinical Oncology |
| DOI | |
| 出版物ステータス | 受理済み/印刷中 - 1 1 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
これを引用
Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma : 10-year experience of a single institute. / Kodama, Keisuke; Sonoda, Kenzo; Kijima, Masako; Yamaguchi, Shinichiro; Yagi, Hiroshi; Yasunaga, Masafumi; Ohgami, Tatsuhiro; Onoyama, Ichiro; Kaneki, Eisuke; Okugawa, Kaoru; Yahata, Hideaki; Ohishi, Yoshihiro; Oda, Yoshinao; Kato, Kiyoko.
：: Asia-Pacific Journal of Clinical Oncology, 01.01.2019.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma
T2 - 10-year experience of a single institute
AU - Kodama, Keisuke
AU - Sonoda, Kenzo
AU - Kijima, Masako
AU - Yamaguchi, Shinichiro
AU - Yagi, Hiroshi
AU - Yasunaga, Masafumi
AU - Ohgami, Tatsuhiro
AU - Onoyama, Ichiro
AU - Kaneki, Eisuke
AU - Okugawa, Kaoru
AU - Yahata, Hideaki
AU - Ohishi, Yoshihiro
AU - Oda, Yoshinao
AU - Kato, Kiyoko
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Aim: Uterine leiomyosarcoma (ULMS) is a highly aggressive and lethal disease. This malignancy remains the most common type of uterine sarcoma, affecting approximately 0.4/100 000 women each year. Our aim was to assess the treatment and prognosis of ULMS patients. Methods: A total of 14 patients were treated at our institution between January 2008 and July 2017. We retrospectively analyzed their clinicopathological variables, treatment and prognosis. Results: The median patient age was 63 years (range, 35–83 years). The largest group of patients had stage IB disease (stage IB, n = 8; IIB, n = 2; IIIB, n = 1; IVB, n = 3) and the largest group by histological subtype was ordinary (ordinary, n = 11; myxoid, n = 2; epithelioid, n = 1). Total abdominal hysterectomy and bilateral salpingo-oophorectomy were performed for all patients, with additional surgical procedures (e.g., tumor resection, lymphadenectomy) performed if necessary. Twelve patients received adjuvant chemotherapy (ACT) consisting of gemcitabine and docetaxel. Ten patients experienced recurrence and received multidisciplinary therapies, including tumor resection, chemotherapy, radiation and targeted therapies. The median observation period was 17 months (range, 5–75 months), and 11 patients were alive (without disease, n = 5; with disease, n = 6). Intriguingly, five of eight stage IB patients who received postoperative ACT were alive without disease. Conclusion: ULMS is rare but is associated with a poor prognosis, even if multidisciplinary therapies are administered. However, ACT appears to be effective in improving the prognosis of patients with stage IB disease.
AB - Aim: Uterine leiomyosarcoma (ULMS) is a highly aggressive and lethal disease. This malignancy remains the most common type of uterine sarcoma, affecting approximately 0.4/100 000 women each year. Our aim was to assess the treatment and prognosis of ULMS patients. Methods: A total of 14 patients were treated at our institution between January 2008 and July 2017. We retrospectively analyzed their clinicopathological variables, treatment and prognosis. Results: The median patient age was 63 years (range, 35–83 years). The largest group of patients had stage IB disease (stage IB, n = 8; IIB, n = 2; IIIB, n = 1; IVB, n = 3) and the largest group by histological subtype was ordinary (ordinary, n = 11; myxoid, n = 2; epithelioid, n = 1). Total abdominal hysterectomy and bilateral salpingo-oophorectomy were performed for all patients, with additional surgical procedures (e.g., tumor resection, lymphadenectomy) performed if necessary. Twelve patients received adjuvant chemotherapy (ACT) consisting of gemcitabine and docetaxel. Ten patients experienced recurrence and received multidisciplinary therapies, including tumor resection, chemotherapy, radiation and targeted therapies. The median observation period was 17 months (range, 5–75 months), and 11 patients were alive (without disease, n = 5; with disease, n = 6). Intriguingly, five of eight stage IB patients who received postoperative ACT were alive without disease. Conclusion: ULMS is rare but is associated with a poor prognosis, even if multidisciplinary therapies are administered. However, ACT appears to be effective in improving the prognosis of patients with stage IB disease.
UR - http://www.scopus.com/inward/record.url?scp=85075060946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075060946&partnerID=8YFLogxK
U2 - 10.1111/ajco.13286
DO - 10.1111/ajco.13286
M3 - Article
C2 - 31721462
AN - SCOPUS:85075060946
JO - Asia-Pacific Journal of Clinical Oncology
JF - Asia-Pacific Journal of Clinical Oncology
SN - 1743-7555
ER -